Table 2

CSF biomarkers in iNPH compared with non-iNPH disorders, cognitive disorders and movement disorders

iNPHNon-iNPH disordersCognitive disordersMovement disorders
n=82n=297n=144n=153
T-tau (pg/mL)245 (131)496 (443)***725 (517)***282 (186)
P-tau (pg/mL)32 (12)54 (36)***72 (38)***37 (22)*
NFL (pg/mL)1717 (1963)1960 (2508)2340 (3147)1603 (1633)
Aβ38 (pg/mL)1526 (519)2194 (794)***2360 (757)***2037 (798)***
Aβ40 (pg/mL)3800 (1193)5428 (1684)***5889 (1610)***4994 (1641)***
Aβ42 (pg/mL)364 (138)454 (197)***387 (182)517 (190)***
sAPPα (pg/mL)446 (178)693 (282)***726 (299)***661 (262)***
sAPPβ (pg/mL)321 (121)498 (188)***527 (193)***471 (179)***
MCP-1 (pg/mL)492 (109)416 (138)***442 (132)*391 (138)***
  • CSF biomarkers in iNPH compared to non-iNPH disorders, cognitive disorders and movement disorders. Concentrations are given as mean and SD. Significance testing was done by one-way ANCOVA corrected for age and sex with Dunnett’s multiple comparisons test and is shown as *p< 0.05, **p< 0.01, ***p<0.001.

  • Aβ, AD-related amyloid β; AD, Alzheimer’s disease; ANCOVA, analysis of covariance; CBD, corticobasal degeneration; CSF, cerebrospinal fluid; Cognitive disorders, AD+FTLD+VAD; FTLD, frontotemporal lobe degeneration; MCP-1, monocyte chemoattractant protein 1; MSA, multiple system atrophy; Movement disorders, PD, MSA, PSP, CBD; NFL, neurofilament light; Non-iNPH disorders, AD+FTLD+VAD+PD+MSA+PSP+CBD; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; P-tau, phosphorylated tau; T-tau, total tau; VAD, vascular dementia; iNPH, idiopathic normal pressure hydrocephalus; sAPP, soluble amyloid precursor protein.